FDA approves new blood test for Alzheimer’s disease
New blood tests offer a simpler way to diagnose Alzheimer's disease, though experts caution these tools are not suitable for everyone. While blood tests might preview risk or identify potential, doctors previously maintained that predictive tools are not yet ready for general use. In the United Kingdom, experts warned that patients risk missing out on breakthrough Alzheimer's treatments because the National Health Service is not ready to deliver them. Meanwhile, individuals can take steps now to lower later-in-life dementia risk without needing a blood test.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ New blood tests offer a simpler way to help diagnose Alzheimer's disease.
- ✓ Experts warned that patients risk missing out on breakthrough Alzheimer's treatments because the NHS is not ready to deliver them.
What changed
New reporting highlights that while blood tests offer a simpler diagnostic route, clinical readiness and patient eligibility remain key hurdles.
Live updates
-
New Blood Tests Simplify Alzheimer's Diagnosis
New blood tests offer a simpler way to diagnose Alzheimer's disease, though experts caution these tools are not suitable for everyone. While blood tests might preview risk or identify potential, doctors previously maintained that predictive tools are not yet ready for general use. In the United Kingdom, experts warned that patients risk missing out on breakthrough Alzheimer's treatments because the National Health Service is not ready to deliver them. Meanwhile, individuals can take steps now to lower later-in-life dementia risk without needing a blood test.
Why it matters
Diagnosing Alzheimer's pathology historically relied on expensive PET scans or specialized evaluations. Recent research from Columbia University indicated that combining a blood test with a genetic test provides a more useful estimate of when symptoms will first appear in high-risk individuals compared to using either test alone. This follows the FDA clearance of the Roche Elecsys pTau217 blood test, which was intended to reduce reliance on PET scans.
What is confirmed
- New blood tests offer a simpler way to help diagnose Alzheimer's disease.
- Experts warned that patients risk missing out on breakthrough Alzheimer's treatments because the NHS is not ready to deliver them.
Still unconfirmed
- Anyone can take steps now to lower their risk of later-in-life dementia without taking a test.
What to watch next
- Wider clinical adoption and readiness of the NHS to deliver breakthrough treatments
- Upcoming educational events such as the Alzheimer's Foundation of America conference on September 16 in New Hampshire
confidence 90%Sources used for this update (9)
- www.timesleader.com — Want to lower your risk of dementia? It doesn’t involve a blood test
- malaysia.news.yahoo.com — NHS ‘not ready’ to deliver breakthrough Alzheimer’s treatments
- www.baltimoresun.com — New blood tests offer a simpler way to help diagnose Alzheimer’s
- www.bostonherald.com — Want to lower your risk of dementia? It doesn’t involve a blood test
- www.nhbr.com — Alzheimer’s Foundation of America bringing free educational conference to New Hampshire on Sept. 16
- www.pharmexec.com — Wendy Short Bartie: Reputation as Currency
- blackpressusa.com — BOOK REVIEW — Curved Air: A Biography of Sickle Cell Anemia and the Quest to Cure the First Molecular Disease
- finance.yahoo.com — BRAINBox and Prolight sign supply agreement for concussion tests
- en.sedaily.com — Painless Lump on Neck May Signal Lymphoma, Doctor Warns
-
Columbia University study suggests combined blood and genetic tests predict Alzheimer's
Researchers at Columbia University found that combining a blood test with a genetic test provides a more useful estimate of when Alzheimer's symptoms will first appear in high-risk individuals than using either test alone. While Labcorp has unveiled a blood test to identify Alzheimer's potential, some doctors maintain that these predictive tools are not yet ready for general use. This development follows previous FDA clearance of the Roche Elecsys pTau217 blood test, which aimed to reduce reliance on expensive PET scans for diagnosing Alzheimer's pathology.
Why it matters
The medical field is shifting toward blood-based biomarkers to detect complex diseases before symptoms emerge. This approach aims to replace invasive imaging and allow for earlier intervention. Current efforts include clinical trials testing if existing drugs can help patients before they show cognitive decline.
What is confirmed
- The FDA previously cleared the Roche Elecsys pTau217 blood test for Alzheimer's pathology.
Still unconfirmed
- Some doctors believe new blood tests that predict Alzheimer's years before symptoms begin are not yet ready.
What to watch next
- Clinical trial results regarding the use of existing drugs to prevent cognitive decline in Alzheimer's patients.
- FDA regulatory decisions on combined blood and genetic testing protocols for symptom prediction.
confidence 70%Sources used for this update (6)
- jen.jiji.com — Mongolia and France agree to strengthen school lunch program
- www.courant.com — Want to lower your risk of dementia? It doesn’t involve a blood test
- www.dailymail.com — Six drugs that could TRANSFORM Parkinson's treatment
- www.postandcourier.com — ‘This is something I can do.’ Charleston man fights to be part of cure for Alzheimer's disease.
- knowridge.com — Two Tests May Show When Alzheimer’s Symptoms Will Begin
- journalnow.com — Labcorp unveils blood test identify potential for Alzheimer's disease in patients
-
FDA Approves Blood-Guided Treatment for Advanced Breast Cancer
The FDA approved a new pill for advanced breast cancer that utilizes a blood test to detect treatment resistance before imaging scans can identify it. This follows previous regulatory clearance of the Roche Elecsys pTau217 blood test for Alzheimer's pathology and the use of screening algorithms to reduce PET scans in clinical trials. These developments signal a shift toward blood-based biomarkers to guide treatment and diagnosis for complex diseases, reducing reliance on invasive or expensive imaging while potentially extending the time before a patient's condition worsens.
Why it matters
Clinicians are increasingly using blood-based biomarkers to rule in or out neurological and oncological conditions early. This approach aims to streamline patient recruitment for trials and personalize drug administration based on real-time biological data.
What is confirmed
- The FDA cleared Roche's Elecsys pTau217 blood test to identify amyloid pathology in adults with cognitive impairment.
- A blood-based screening algorithm has reduced the number of unnecessary PET scans used to recruit Alzheimer's patients for clinical trials.
Still unconfirmed
- A blood test for breast cancer can spot resistance before a scan does.
What to watch next
- Further FDA approvals of blood-based biomarkers for other neurodegenerative diseases.
confidence 90%Sources used for this update (8)
- jen.jiji.com — AI-designed drug may slow signs of human aging
- jen.jiji.com — Kazakh president approves new regulations for Security Council and its Office
- www.pharmabiz.com — US FDA grants Priority Review status to Roche’s sBLA for Enspryng for MOGAD, an autoimmune disease with no approved treatments
- rocklandtimes.com — September Is a Good Month to Talk About Memory
- jen.jiji.com — Africa CDC warns Ebola spreading beyond eastern Congo epicentre
- www.rttnews.com — New FDA Drug Approvals - August 2026
- jen.jiji.com — Robot conductor leads Kurmangazy Orchestra’s 93rd concert season opener
- www.yahoo.com — New drug for advanced breast cancer guided by blood test approved by FDA
-
New Screening Tool Cuts Unnecessary Alzheimer PET Scans
A blood-based screening algorithm has dramatically reduced the number of unnecessary PET scans required to recruit patients at risk of Alzheimer's disease for clinical trials. Published in the journal Alzheimer's and Dementia, research from scientists at the Keck School of Medicine of USC shows that this algorithmic approach improves how patients are screened. This breakthrough follows the FDA clearance of Roche's Elecsys pTau217 blood test, which helps clinicians identify amyloid pathology in adults with cognitive impairment and rule the condition in or out early.
Why it matters
Diagnosing Alzheimer's disease before significant brain damage occurs remains a central hurdle for clinical trials and patient care. Traditional recruitment methods often rely on expensive and invasive procedures like PET scans. Integrating blood-based screening algorithms and newly cleared diagnostics aims to streamline trial enrollment and patient management significantly.
What is confirmed
- A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial.
- The research was conducted by scientists at the Keck School of Medicine of USC and published in the journal Alzheimer's & Dementia.
What to watch next
- Adoption rates of the new blood-based screening algorithm in other clinical trials
- Further peer-reviewed validation of the USC Keck School of Medicine screening tool
confidence 100%Sources used for this update (8)
- www.today.com — Is There a Summer COVID Surge? With Cases Rising in Nearly Every State, Watch for These Symptoms
- jen.jiji.com — Kazakhstan's bank assets rise to 75.6 trillion tenge
- medicalxpress.com — Algorithmic tool may improve screening of patients for an Alzheimer's clinical trial
- jen.jiji.com — Kazakhstan, Switzerland hold 7th round of political consultations
- www.news-medical.net — New blood screening algorithm reduces unnecessary Alzheimer's PET scans
- www.miragenews.com — Test Combo Predicts Alzheimer's Years in Advance
- www.insideprecisionmedicine.com — Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?
- www.finanznachrichten.de — F. Hoffmann-La Roche Ltd: U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approved treatments
-
FDA approves Roche blood test for Alzheimer's pathology
The FDA has cleared the Elecsys pTau217 blood test from Roche, providing clinicians a less invasive method to identify amyloid pathology in adults with cognitive impairment. This diagnostic tool helps rule in or rule out Alzheimer's disease before significant brain damage occurs. To build on this diagnostic capability, Roche has launched the PrevenTRON trial in the UK. This study tests the drug trontinemab on patients with preclinical Alzheimer's disease to advance treatment options for those in the earliest stages of the condition.
Why it matters
Early detection of amyloid pathology is critical for initiating interventions before irreversible neurological decline. The combination of a blood-based diagnostic and targeted therapeutics represents a shift toward preclinical management of the disease.
What is confirmed
- The FDA cleared the Elecsys pTau217 blood test to identify amyloid pathology in adults with cognitive impairment.
- Roche launched the PrevenTRON trial in the UK to test trontinemab on patients with preclinical Alzheimer's disease.
What to watch next
- Results from the PrevenTRON trial regarding trontinemab efficacy
- Further FDA clearances for preclinical Alzheimer's therapeutics
confidence 100%Sources used for this update (7)
- inews.co.uk — HMRC delays cost me £323 – hundreds of thousands of parents are at risk
- www.nationalgeographic.com — Why GLP-1s Could Be an Anti-Aging Breakthrough
- www.theglobeandmail.com — A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
- finance.yahoo.com — Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- finance.yahoo.com — IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival ...
- www.thestar.com.my — Early data indicates an AI-generated drug could slow ageing
- muddyriversports.com — VapoCept Reviews and Complaints 2026 – Legit Cognitive Support Formula or Overhyped? What the Research Actually Shows
-
Roche begins European trials for Alzheimer's drug trontinemab
Roche has launched the PrevenTRON trial in the UK to test its Brainshuttle drug trontinemab on patients with preclinical Alzheimer's disease. This therapeutic push follows the FDA's clearance of Roche's Elecsys pTau217 blood test, which allows clinicians to identify amyloid pathology in adults with cognitive impairment. While the blood test provides a less invasive way to rule in or rule out the disease before significant brain damage occurs, the trontinemab trial seeks to advance treatment options for those in the earliest stages of the condition.
Why it matters
Early detection of amyloidosis traditionally requires expensive or inaccessible procedures. Moving toward blood-based diagnostics and preclinical drug trials aims to treat the disease before severe cognitive decline.
What is confirmed
- The PrevenTRON trial of Roche's Brainshuttle drug trontinemab has begun in the UK for preclinical Alzheimer's disease.
- The FDA cleared Roche Holding's Elecsys pTau217 blood test to help clinicians rule in and rule out amyloid pathology in Alzheimer's disease.
What to watch next
- Results from the PrevenTRON trial regarding trontinemab efficacy
- FDA decisions on additional biomarkers for dementia diagnosis
confidence 100%Sources used for this update (7)
- medicalxpress.com — Understudied gut fungus may help repair radiation-damaged DNA and limit intestinal injury
- www.unilad.com — New research reveals futuristic side effect Ozempic could have and it's more than just weight loss
- pharmaphorum.com — Major trial of Roche Alzheimer's drug kicks off in Europe
- www.alzheimersresearchuk.org — How Alzheimer’s Research UK helped develop blood tests for Alzheimer’s
- www.dailymail.com — Experimental cancer drug could stop osteoporosis and help women stay slim after menopause
- www.news-medical.net — Experimental cancer drug could protect against osteoporosis and weight gain
- www.insidermonkey.com — Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
-
Roche Wins FDA Clearance for Alzheimer's Blood Test
The U.S. Food and Drug Administration has cleared Roche Holding's Elecsys pTau217 blood test as the first single biomarker assay designed to help clinicians both rule in and rule out amyloid pathology in Alzheimer's disease. The diagnostic tool is intended to support physicians in evaluating adult patients showing symptoms of cognitive impairment earlier in the condition's progression. Traditional procedures for identifying amyloidosis are often expensive or difficult to access, making this simpler and less invasive option a significant shift for clinical access. The test functions as an early evaluation aid before significant brain damage occurs.
Why it matters
Alzheimer's disease diagnostics have historically relied on expensive or difficult-to-access procedures to confirm or rule out amyloidosis. Introducing a single biomarker blood test allows clinicians to evaluate patients more easily at earlier stages of cognitive impairment. Roche developed the Elecsys pTau217 assay to assist physicians in managing patient evaluation workflows.
What is confirmed
- The FDA cleared Roche Holding's Elecsys pTau217 blood test to help physicians evaluate patients for Alzheimer's disease.
- The Elecsys pTau217 test is the first single biomarker assay to help both rule in and rule out amyloid pathology in Alzheimer's disease.
- The test is intended to support clinicians in earlier evaluation of adult patients showing symptoms of cognitive impairment.
What to watch next
- Commercial rollout and pricing announcements for the Elecsys pTau217 test
- Adoption rates among clinical practices and memory centers
confidence 100%Sources used for this update (10)
- jen.jiji.com — Popular weight-loss drug shows anti-aging effects
- jen.jiji.com — Almaty oncology center introduces robotic pharmacy system
- finance.yahoo.com — Roche Holding (SWX:ROP) Received FDA Clearance For An Alzheimer’s Blood Test
- medicaldialogues.in — FDA Grants Accelerated Approval to a New Breast Cancer Treatment
- www.sciencedaily.com — A simple blood test could detect multiple cancers and reveal where they started
- www.news-medical.net — New prostate cancer screening advances improve early detection
- jen.jiji.com — Kazakhstan expands exploration plans with up to 200 new wells
- jen.jiji.com — Death toll from mudslide in Nepal rises to 1,355, nearly 5,000 missing
- www.news-medical.net — Genetic COPD risk emerges early with higher air pollution
- finance.yahoo.com — Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease
-
FDA clears Elecsys pTau217 blood test for Alzheimer's assessment
The FDA has cleared Elecsys pTau217, a blood test developed by Roche Holding AG and Eli Lilly and Company to help physicians evaluate patients for Alzheimer's disease. The test offers a simpler, less invasive alternative to traditional diagnostic procedures that are often expensive or difficult to access. It is available to adults aged 40 and older who show symptoms of cognitive impairment, allowing clinicians to confirm or rule out amyloidosis early in the disease's progression before significant brain damage occurs.
Why it matters
Traditional Alzheimer's diagnostics often require invasive or costly procedures. Early detection is critical because clinical symptoms typically emerge only after substantial neurological damage has already taken place.
What is confirmed
- The FDA cleared the Elecsys pTau217 blood test to help identify Alzheimer's-related brain changes.
- Roche Holding AG and Eli Lilly and Company developed the blood test.
- The test is for adults 40 and older with symptoms of cognitive impairment.
- The test provides a less invasive alternative to traditional diagnostics that are often expensive or difficult to access.
What to watch next
- Clinical adoption rates of Elecsys pTau217 in primary care settings
- Availability of the test across different healthcare providers
confidence 100%Sources used for this update (5)
- finance.yahoo.com — Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
- www.bostonglobe.com — Alzheimer’s patients deserve to know their diagnosis
- www.news-medical.net — ART-conceived children show reassuring long-term health outcomes
- knowridge.com — Early Warning Signs of Pancreatic Cancer You Should Never Miss
- www.yahoo.com — NHS trust joins Alzheimer's prevention drug trial
-
FDA Clears Blood Test for Alzheimer Disease Diagnosis
The FDA approved a blood test for Alzheimer disease available to adults aged 40 and older showing symptoms of cognitive impairment. This test provides a less invasive and more accessible alternative to traditional diagnostic procedures that are often expensive or difficult to access. The test allows clinicians to confirm or rule out amyloidosis early in the disease progression, which is critical because symptoms typically appear after significant brain damage has occurred.
Why it matters
Alzheimer's is a brain disorder where early detection is difficult. Previous diagnostic methods relied on invasive or costly procedures. This new tool supports early intervention as diagnoses rise among people in their 50s and 60s.
What is confirmed
- The FDA approved a blood test to diagnose Alzheimer disease.
- Adults aged 40 years and older with symptoms of cognitive impairment may qualify for the blood test.
Still unconfirmed
- Diagnoses of dementia are rising in people in their 50s and 60s.
What to watch next
- Clinical trial results for BPN14770 regarding memory loss and nerve damage.
confidence 90%Sources used for this update (6)
- www.ynetnews.com — Dementia doesn’t always begin with memory loss: early warning signs to watch for
- www.aol.com — ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
- www.neurologyadvisor.com — FDA Clears Blood Test for Alzheimer Disease
- www.wamc.org — Health Your Self: Losing it - or not
- www.insidermonkey.com — Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?
- www.raps.org — This Week at FDA: Foreign clinical trial scrutiny, botanical drugs, and an EUA declaration
-
FDA Approves New Blood Test For Alzheimer’s Disease
The US Food and Drug Administration has approved the first-ever blood test to diagnose Alzheimer's disease early, providing a way to confirm or rule out amyloidosis. Alzheimer's is a brain disorder with symptoms appearing after much of the damage is done. Additional research indicates that a drug called BPN14770 can help treat memory loss and nerve damage, while another study revealed that a process called axon myelination is significantly disrupted in patients. Meanwhile, an Alzheimer's trial by Annovis surpassed its enrollment goal by signing up 850 patients.
Why it matters
Early detection remains critical for brain disorders because current treatments work best in the early stages. Traditional symptoms often manifest long after significant neural damage has already occurred. Diagnostic tools such as blood tests aim to streamline the identification process for clinicians and patients.
What is confirmed
- The US Food and Drug Administration approved a new test to confirm or rule out the presence of amyloidosis and diagnose Alzheimer's disease early.
Still unconfirmed
- A drug called BPN14770 can help treat memory loss and nerve damage according to research published in the Journal of Pharmacology and Experimental Therapeutics.
- Axon myelination is significantly disrupted in patients with Alzheimer's according to a study published in the journal Nature.
- An Alzheimer's trial by Annovis enrolled 850 patients, exceeding its target of 760.
- Childhood vaccination rates are declining throughout the United States.
What to watch next
- Broad commercial rollout and pricing details for the newly approved blood test
- Further clinical trial results from Annovis regarding its Alzheimer's treatment pill
- Peer-reviewed findings on drug treatments like BPN14770 and axon myelination
confidence 100%Sources used for this update (4)
- sg.news.yahoo.com — ‘Setup For A Disaster’: Pediatricians Predict Will Happen If Vaccination Rates Continue To Fall
- en.ilsole24ore.com — Alzheimer’s: a new ‘two-in-one’ blood test to detect the disease is on the way
- Longevity.Technology — Annovis sails past enrollment goal on Alzheimer’s
- www.thehealthsite.com — Alzheimer's Blood Test
-
FDA Approves Elecsys pTau-217 Blood Test for Alzheimer's
The US FDA has approved the Elecsys pTau-217 blood test for Alzheimer's disease, developed by Roche and Eli Lilly. The test, available for adults 55 and older with cognitive decline, offers a less invasive diagnostic alternative. Labcorp will provide the test in primary and specialty care settings. Early detection is crucial as current FDA-approved treatments are most effective in the disease's early stages.
Why it matters
Alzheimer's disease is a progressive neurological disorder with no cure, but early detection can significantly impact treatment effectiveness. Traditional diagnostic procedures can be invasive and costly. The approval of this blood test marks a significant advancement in Alzheimer's diagnosis and management.
What is confirmed
- The Elecsys pTau-217 blood test was developed in collaboration by Roche and Eli Lilly.
- The test is intended for adults 55 and older with signs or symptoms of cognitive decline.
- Labcorp will provide the Elecsys pTau-217 blood test in primary and specialty care settings.
What to watch next
- Availability and pricing of the Elecsys pTau-217 blood test
- Impact on Alzheimer's disease diagnosis and treatment rates
- Potential updates on the test's effectiveness and limitations
confidence 100%Sources used for this update (6)
- jen.jiji.com — Imola, man found dead at home covered in blood: wife arrested
- www.medicalbrief.co.za — First single-biomarker blood test for Alzheimer's approved
- www.psychologytoday.com — Can a Blood Test Predict Your Risk of Alzheimer’s Disease?
- jen.jiji.com — Kazakhstan’s top short-track athlete Abzal Azhgaliyev announces retirement
- www.news-medical.net — New app aims to boost prostate cancer screening among Black men
- www.nbcnews.com — Doctors fill CDC guidance void with new vaccine recommendations
-
FDA-approved Alzheimer's blood test available via Labcorp
The US FDA has approved Elecsys pTau-217, a blood test for Alzheimer's disease developed by Roche and Eli Lilly. Labcorp will provide the test for adults 55 and older experiencing cognitive decline in primary and specialty care settings. This diagnostic tool offers a less invasive alternative to traditional procedures. Early detection is essential because current FDA-approved prescriptions are most effective when used during the earliest stages of the disease.
Why it matters
Traditional Alzheimer's diagnostics often involve more invasive methods. Rapid identification allows patients to begin treatment during the window of maximum efficacy.
What is confirmed
- The FDA approved the Elecsys pTau-217 blood test for Alzheimer's disease.
- Roche and Eli Lilly developed the Elecsys pTau-217 test.
- Labcorp will provide the test for adults aged 55 and older with cognitive decline.
What to watch next
- Clinical data on the impact of early detection via pTau-217 on patient outcomes
- Expansion of test availability to additional laboratory providers
confidence 100%Sources used for this update (6)
- jen.jiji.com — Rett Syndrome, EU approval for neurobehavioral symptom treatment
- jen.jiji.com — 6 killed in road accident on Saryozek-Koktal highway
- www.news-medical.net — New method based on human blood simplifies mRNA drug development
- jen.jiji.com — Kazakhstan to simplify companies' access to stock market
- jen.jiji.com — Inter, Ausilio will not renew contract: leaves club after 28 years
- www.dailymail.com — Trial for autoimmune disease treatment urgently halted after multiple participants die
-
FDA Approves Blood Test for Alzheimer’s Disease
The US FDA has approved a blood test for Alzheimer’s disease developed by Roche and Eli Lilly. The test, called Elecsys pTau-217, will be provided by Labcorp in specialty and primary care settings for adults 55 and older with cognitive decline. This test offers a less invasive alternative to traditional diagnostic procedures. Early detection is critical as current FDA-approved prescriptions are most effective when administered during the earliest stages of the disease.
Why it matters
Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide. Early detection and diagnosis are crucial for effective treatment and management. The approved blood test is expected to improve diagnosis and treatment options for patients with Alzheimer’s disease.
What is confirmed
- The US FDA has cleared the Elecsys pTau-217 blood test, a diagnostic tool developed by Roche and Eli Lilly to detect Alzheimer's disease pathology.
- Labcorp will provide the single-biomarker test in specialty and primary care settings for adults 55 and older exhibiting cognitive decline.
- The test uses a single vial of blood to identify biomarkers, offering a less invasive alternative to traditional diagnostic procedures.
What to watch next
- The effectiveness of the Elecsys pTau-217 blood test in real-world settings
- The impact of the test on Alzheimer's disease diagnosis and treatment rates
- Potential updates on the test's availability and accessibility
confidence 100%Sources used for this update (13)
- jen.jiji.com — Turkmenistan takes measures to expand power generation capacity
- jen.jiji.com — ADB approves $5 million emergency grant for Nepal flood relief
- www.dailymail.com — What 'healthy' electrolytes are really doing to your body: They've exploded in popularity in recent years but now our experts warn how they could cause you serio…
- jen.jiji.com — US Open, today Djokovic-Navone: schedule, head-to-head, and where to watch it on TV
- jen.jiji.com — Lazio, injury for Rovella: he stops with Genoa
- jen.jiji.com — IOC hails Kurbanov’s Olympic triumph, calls him a b‑boy
- jen.jiji.com — Ranucci Case, Report journalists' assembly: "State of agitation, we will strike if necessary"
- www.crescent-news.com — Michael Roizen, M.D.: Optimize your child's health; recovering from fatty liver disease
- jen.jiji.com — Qurultay to align legislation with new Constitution, focus on AI and energy
- www.yahoo.com — FDA approves new blood test for Alzheimer’s
- www.dailymail.com — The 'Ozempic for the brain' pill that could tackle sleep disorders, ADHD and depression...and why scientists believe it's the biggest breakthrough in 30 years
- jen.jiji.com — Tatarstan to host World Nomad Games in 2028, Kyrgyz President
-
FDA Clears Roche Elecsys pTau-217 Blood Test for Alzheimer's Disease
The US FDA has cleared the Elecsys pTau-217 blood test, a diagnostic tool developed by Roche and Eli Lilly to detect Alzheimer's disease pathology. Labcorp will provide the single-biomarker test in specialty and primary care settings for adults 55 and older exhibiting cognitive decline. The test uses a single vial of blood to identify biomarkers, offering a less invasive alternative to traditional diagnostic procedures. Early detection is critical because current FDA-approved prescriptions are most effective when administered during the earliest stages of the disease.
Why it matters
Traditional Alzheimer's diagnostics often require invasive methods to confirm pathology. This blood-based approach allows clinicians to identify the disease sooner. Earlier diagnosis enables the use of medications that target the disease before significant symptom progression.
What is confirmed
- The FDA cleared the Elecsys pTau-217 blood test for Alzheimer's disease.
- Roche and Eli Lilly developed the single-biomarker diagnostic.
- Labcorp will offer the test in primary and specialty care settings.
- The test is intended for adults aged 55 and older showing signs of cognitive decline.
- The diagnostic identifies biomarkers using a single vial of blood.
What to watch next
- Clinical data on the impact of early detection via pTau-217 on patient outcomes
- Updates on the rollout schedule for Labcorp clinics across the US
confidence 100%Sources used for this update (7)
- www.rttnews.com — Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal
- jen.jiji.com — Strong wave of bad weather hits Northern Italy: cloudburst and whirlwind in Cremona, cable car stopped in Trentino
- jen.jiji.com — Germany, Hormuz talks postponed in Istanbul
- finance.yahoo.com — Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer’s Blood Test
- jen.jiji.com — Scientists find new way to disarm deadly fungus
- www.wfmz.com — Health Beat: Blood test helps detect Alzheimer's disease early
- jen.jiji.com — Kazakhstan names robotics team for FIRST Global Challenge 2026 as it eyes fifth straight win
-
Labcorp to deploy FDA-cleared Elecsys pTau-217 Alzheimer's blood test
Labcorp will offer the Elecsys pTau-217 blood test in primary and specialty care settings following US FDA clearance. Developed by Roche and Eli Lilly, the single-biomarker test detects Alzheimer's disease pathology using a blood sample rather than invasive methods. The diagnostic is intended for adults aged 55 and older who show signs of cognitive decline. By identifying biomarkers in a single vial of blood, the tool helps clinicians detect the disease earlier and provides a less invasive alternative to traditional diagnostic procedures.
Why it matters
Early detection of Alzheimer's is critical for managing cognitive decline and accessing potential treatments. Traditional diagnostics often require invasive lumbar punctures or expensive imaging. This blood-based approach simplifies the screening process for healthcare providers.
What is confirmed
- The US FDA cleared the Elecsys pTau-217 single-biomarker blood test to detect Alzheimer's disease pathology.
- Labcorp will provide the Elecsys pTau-217 test in specialty and primary care settings.
- The test is designed for adults 55 and older experiencing cognitive decline.
- Roche and Eli Lilly developed the biomarker blood test.
What to watch next
- Clinical data on the test's accuracy compared to traditional cerebrospinal fluid analysis
- Insurance coverage determinations for the Elecsys pTau-217 test
confidence 100%Sources used for this update (11)
- pharmabiz.com — Labcorp to offer Elecsys pTau-217 test, an US FDA-cleared blood test to detect Alzheimer's disease pathology in both primary and specialty care settings
- finance.yahoo.com — Eli Lilly Clears Big Hurdle in Alzheimer's Fight
- www.inquirer.com — You want to join a clinical trial. Here's what to know about the hurdles.
- www.yahoo.com — New Alzheimer's blood test could help doctors detect disease earlier
- inews.co.uk — I’m a millionaire’s assistant on £85,000 – the weirdest things I’ve been asked to do
- medicalxpress.com — Writing the next bible of psychiatry: For the first time, the DSM will use biology to understand mental disorders
- elifesciences.org — Prenatal Alcohol Exposure Disrupts γ-Secretase Activity and Impairs Learning and Memory in Wild-Type and 3xTg-AD Mice
- www.aol.com — FDA clears first single-biomarker blood test for Alzheimer’s: 4 experts weigh in
- jen.jiji.com — MotoGp, today free practice and pre-qualifying: times and where to watch them on TV (free-to-air)
- jen.jiji.com — King Harald V dies at 89, Norway mourns its monarch
- www.detroitnews.com — Want to join a clinical trial? Be prepared for hurdles
-
FDA Approves Roche and Eli Lilly Alzheimer's Blood Test
The US Food and Drug Administration approved a first-of-its-kind biomarker blood test developed by Roche and Eli Lilly to detect signs of Alzheimer's disease. The test is intended for adults aged 55 and older who are already experiencing cognitive decline. Roche announced the approval on August 24. This diagnostic tool allows clinicians to identify Alzheimer's markers through a blood sample rather than more invasive methods.
Why it matters
Early and accurate detection of Alzheimer's is critical for initiating treatment and planning care. Traditional diagnostics often require expensive imaging or invasive spinal taps. This biomarker test provides a less invasive alternative for screening symptomatic older adults.
What is confirmed
- The FDA approved an Alzheimer's biomarker blood test developed by Roche and Eli Lilly.
- The test is designed for people aged 55 and older showing signs of cognitive decline.
- Roche announced the FDA approval on August 24.
What to watch next
- Clinical adoption rates among healthcare providers
- Insurance coverage determinations for the new test
- Long-term efficacy data on patient outcomes following blood-test diagnosis
confidence 100%Sources used for this update (8)
- WSJ — FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
- Fierce Biotech — Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test
- Reuters — Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance
- The Washington Post — FDA approves a new blood test to detect signs of Alzheimer’s
- The Hill — FDA approves new blood test for Alzheimer’s disease
- www.aha.org — FDA approves new Alzheimer’s blood test
- www.yahoo.com — FDA Approves New Blood Test to Identify Signs of Alzheimer’s
- malaysia.news.yahoo.com — Another Alzheimer’s blood test gets OK from FDA
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community